Our Story
From early academic experiments to a certified clinical medical device, VDI Technologies grew through long-term collaboration between engineers, researchers, and electrophysiology experts.
First UHF‑ECG research activities initiated.
Clinical validation of early UHF‑ECG prototypes.
VDI Technologies founded.
ISO 13485 certification achieved.
CE Mark obtained for VDI UHF‑ECG.
International clinical collaborations and expansion.
Academic Beginnings
In 2013, a research team from the Institute of Scientific Instruments of the Czech Academy of Sciences in Brno, led by Pavel Jurak, conducted the first ultra-high-frequency ECG (UHF-ECG) experiments in collaboration with Pavel Leinveber and his group at St. Anne’s University Hospital, Brno. The team analyzed ECG signals with a 2 kHz bandwidth sampled at 5 kHz, revealing clinically relevant high-frequency components up to 1.5 kHz.
Software for computing high-fidelity signal envelopes was developed, laying the foundation for further exploration of UHF-ECG dynamics. Subsequent clinical studies focused on monitoring ventricular asynchrony, waveform morphology, and amplitude variations across leads.
Over the years, signal‑processing methods were progressively refined, culminating in the introduction of 2D time‑frequency averaging within the 150–1000 Hz band in 2019. The collaboration expanded to University Hospital Královské Vinohrady in Prague under the leadership of Karol Curila. An ISI‑coordinated EU structural grant then enabled the design of the VDI Monitor as a hardware‑software system capable of reliably detecting and real-time analyzing high‑quality UHF‑ECG signals.
The first VDI UHF-ECG monitor was completed in 2019 and used in multiple clinical studies conducted by the founding institutions. These studies were successfully published and well received in the scientific community.
Commercial Development
Commercial development began in 2021, when Nilus Medical LLC designed the VDI4QECG signal amplifier, tested for mechanical, electrical, and EMC safety in 2022. The investigational system was used under IRB approval in more than 30 research centres across Great Britain, the Netherlands, the Czech Republic, Spain, Italy, South Africa, Bulgaria, and Hungary.
The VDI Vision software was developed and validated using a database of over 10,000 recorded cases. Under the leadership of Miroslav Navratil, appointed CEO in April 2022, VDI Technologies was founded by a group of individual founders and original research institutions.
Convertible loan financing was provided by Cardion, a Brno-based company that later became the lead investor in the first financing round. In 2024, VDI Technologies obtained ISO 13485 certification. The VDI UHF-ECG system, officially recognized as a CE-certified medical device in 2025, marks its entry into clinical medicine.
Clinical & Research Network
VDI Technologies works with clinical and research partners to advance non-invasive cardiac diagnostics and pacing optimization.
Contact Us
For clinical, research, or product inquiries, please contact VDI Technologies directly.